Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharmaceuticals (ALNY) PT Lowered to $116 at BMO Capital
November 8, 2018 8:56 AM ESTBMO Capital analyst Do Kim lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $124.00) while maintaining a Outperform rating.
Kim commented, "We lower our estimates and target price to $116 from $124, following 3Q18 earnings that saw modest initial Onpattro sales... More
Alnylam Pharmaceuticals (ALNY) PT Lowered to $135 at Needham & Company
November 7, 2018 1:35 PM ESTNeedham & Company analyst Alan Carr lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $135.00 (from $152.00) while maintaining a Buy rating.
Carr commented, "Alnylam reported $0.5M in 3Q18 Onpattro sales, but mgmt noted that 125 U.S. patient start forms were submitted to Alnylam... More
Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
November 7, 2018 8:06 AM ESTAlnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($2.43), $0.42 worse than the analyst estimate of ($2.01). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $18.23 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More